Overview of real-world treatment patterns and clinical outcomes with [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Overview of real-world treatment patterns and clinical outcomes with [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Caption

Graphical Abstract: Overview of real-world treatment patterns and clinical outcomes with [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer treated within the French Early-Access Program. The figure summarizes patient population, treatment exposure, efficacy outcomes, and safety findings from routine clinical practice.

Credit

Image created by KPL, Paris.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.